Skip to main content
Skip to main content
Go to homepage

Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Description:

For complete study information, please view the study on clinicaltrials.gov

This study is being done in collaboration with Cincinnati Children's Hospital.

 

Study Status:
Closed
Study Sponsor:

Children’s Oncology Group

Full IRB Study Title:
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
IRB Study ID:
1118157-1
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research, Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.